医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

GORE® EXCLUDER® Iliac Branch Endoprosthesis is First Dedicated System of Its Kind Registered in Australia and New Zealand

2015年05月13日 AM08:00
このエントリーをはてなブックマークに追加


 

FLAGSTAFF, Ariz.

W. L. Gore & Associates (Gore) today announced the GORE® EXCLUDER® Iliac Branch Endoprosthesis, the first complete, fully engineered system (Gore designed iliac branch and internal iliac components) intended for endovascular treatment of common iliac artery aneurysms or aortoiliac aneurysms, has been included on the Australian Register of Therapeutic Goods. The first patient procedures in Australia were successfully completed by vascular surgeons Dr. Steven Dubenec, Head of Department of Vascular Surgery at Royal Prince Alfred Hospital, Sydney, and Dr. Jack Loa, at Macquarie University Hospital, Sydney.

This new device — used in conjunction with GORE® EXCLUDER® AAA Endoprosthesis components to isolate the common iliac artery from systemic blood flow and preserve blood flow in the external iliac and internal iliac arteries — is built on Gore’s proven technology platform and designed using the same durable, expanded polytetrafluoroethylene (ePTFE) graft.

“Based on the design of the GORE® EXCLUDER® Device, this system provides a wide treatment range and long-term durability, which is extremely important for optimal clinical success,” said Dr. Dubenec. “The pre-cannulated branch and bi-femoral delivery elements of the GORE EXCLUDER Iliac Branch Endoprosthesis support the ease of use of this device.”

The GORE EXCLUDER Iliac Branch Endoprosthesis system provides a treatment range of 6.5-13.5 mm for the internal iliac arteries, and a treatment range of 6.5-25 mm for the external iliac arteries. The delivery profile of the loaded catheter allows the use of a 16 Fr introducer sheath for the iliac branch component, and a 12 Fr flexible, reinforced introducer sheath for the internal iliac component.

“This new, fully engineered system builds off the trusted performance of the GORE EXCLUDER AAA Endoprosthesis, providing physicians with a minimally invasive treatment option for iliac repair,” said Ryan Takeuchi, Gore Aortic Business Leader. “We have made great strides in advancing our GORE EXCLUDER Device and branch endoprosthesis portfolio and remain committed to making these innovative devices available to more patients across the world.”

The GORE EXCLUDER Iliac Branch Endoprosthesis is part of the growing family of GORE EXCLUDER Device products that share a mission to effectively treat aortic aneurysms through minimally invasive means, backed by Gore’s highly rated clinical support team and comprehensive educational offerings.

ABOUT US

At Gore, we have provided creative therapeutic solutions to complex medical problems for more than 35 years. During that time, more than 35 million innovative Gore Medical Devices have been implanted, saving and improving the quality of lives worldwide. Our extensive family of products includes vascular grafts, endovascular and interventional devices, surgical meshes for hernia and soft tissue reconstruction, staple line reinforcement materials, and sutures for use in vascular, cardiac, and general surgery. We are one of a select few companies to appear on all of the US “100 Best Companies to Work For” lists since the rankings debuted in 1984. For more information, visit www.goremedical.com.

Products listed may not be available in all markets. GORE®, EXCLUDER®, and designs are trademarks of W. L. Gore & Associates.

CONTACT

Chempetitive Group for W. L. Gore & Associates
Rachel Wallace,
(781) 775-3640
GoreMedical@Chempetitive.com

同じカテゴリーの記事 

  • Parse Biosciences与Hamilton、Opentrons Labworks和SPT Labtech合作推出实验室自动化供应商计划
  • Charting New Paths: Mannatech Expanding with Thailand Office, Grand Opening, September 2024
  • Exergen起诉Baxter International,以捍卫其公布口腔体温计准确性数据的权利
  • Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
  • HighField Biopharmaceuticals Announces Two Abstracts Accepted for the 2024 ASCO Annual Meeting